EGFR and neoplasm: T790M mutations exists as dominant clones in about 50% of patients with acquired resistance, and subclonal populations of EGFR mutant tumor cells with or without the T790M mutation can coexist in EGFR mutant NSCLC that has acquired resistance to EGFR-TKIs.